Evidence map›Paper›PMID 30187130›Full record

ArticleLung2018

Greater Access to Long Acting Beta

Eduardo Vieira Ponte, Álvaro A Cruz, Valmar Bião Lima, Rafael Stelmach, Giovanni Viegi

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Eduardo Vieira PonteFaculdade de Medicina de Jundiaí, R. Francisco Teles, 250, Jundiaí, SP, 13202-550, Brazil. evponte@yahoo.com.br.
Álvaro A CruzNúcleo de Excelência em Asma, Salvador, Brazil.
Valmar Bião LimaNúcleo de Excelência em Asma, Salvador, Brazil.
Rafael StelmachInstituto do Coração, São Paulo, Brazil.
Giovanni ViegiNational Research Council, Rome, Italy.
Faculdade de Medicina de Jundiaí · BRHospital do Coração · BRNational Research Council · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLong Acting Beta

methodsThis is a longitudinal large-scale real-life study. We calculated COPD HA rate and the number of subjects per 10

resultsIn Brazil, COPD HA rate reduced 59% among subjects between 40 and 59 years of age and 60% among subjects older than 59 years of age. Most of the 5506 Brazilian municipalities reduced COPD HA rate [4149 (75%) municipalities & 1357 (25%) municipalities]. The dispensation of LABA was greater among municipalities that reduced COPD HA rate. In the 40-59 age group, the gap in LABA dispensation between the two groups of municipalities increased during the study period from 90.40 to 614.28 subjects per 10

conclusionsCOPD HA rate reduced in Brazil. LABA dispensation growth was associated with COPD HA rate reduction.

Indexed as

Adrenergic beta-2 Receptor AgonistsAdultBrazilCitiesDelayed-Action PreparationsHospitalizationHumansLongitudinal StudiesMiddle AgedPulmonary Disease, Chronic ObstructiveAdrenergic beta-2 Receptor AgonistsDelayed-Action PreparationsCOPDEpidemiologyHospitalizationPublic healthTreatment

Identifiers

PMID30187130
OpenAlexW2891328738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.